Othe r The companys other advertised products comprises Sensipar cinacalcet, Vectibix panitumumab and Nplate romiplostim. Sensipar is the companys registered trademark within the United States and Mimpara is its registered trademark in Europe, for the companys first small molecule medicine utilized in treating CKD sufferers on dialysis who produce an excessive amount of parathyroid hormone, autocad initiatives condition called secondary hyperparathyroidism. Vectibix is the companys trademark for its first absolutely human monoclonal antibody for the remedy of patients with Epidermal Growth Factor Receptors EGFr expressing metastatic colorectal cancer mCRC after disease development on, or following fluoropyrimidine , oxaliplatin and irinotecan containing chemotherapy regimens. On Aug. 22, 2008, the Food and Drug Administration of Untied States FDA accepted Nplate, the platelet manufacturer for the remedy of thrombocytopenia in splenectomized spleen got rid of and non splenectomized adults with persistent immune thrombocytopenic purpura ITP. Nplate, the FDA authorised peptibody protein, works by raising and maintaining platelet counts.